Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (75)	11/8/2002 6:35:27 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 566

No way man, cheaper is better, buy some more next week. I don't really care about a little manipulation on low volume. You watch, this will be $3 in January on the seasonal run up. And the fellow who loads up at a buck will have a nice profit. I own it at $1 1/2. Not averaging down. That said, I just locked another 20% of my worth in a government treasury fund. I'm too chicken to practice what I preach, heheh. So, YOU load up on RIGL here! Don't forget the conference call on the 13th.

To: keokalani'nui who wrote (75)	11/8/2002 8:51:56 PM
From: mopgcw	Respond to of 566

insouciance (What a great word to pull out...) or large cajones of confidence/naivete that more funding will be available given a p2 and two more moving to p1 in the next 12 mos. So far, to the best of my limited knowledge, they have been executing. Gave them the benefit of the doubt and averaged down @ 1.5 two days ago...should have given everyone a heads-up on the clear contrarian short signal that I reliably supply...

To: keokalani'nui who wrote (75)	12/17/2002 2:30:12 PM
From: tuck	Read Replies (1) \| Respond to of 566

Well, these guys are about due: >>During the company's presentation at the CIBC World Markets Healthcare Conference, Rigel said that it intends to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the company's first product, R112 for allergic rhinitis, before the end of the year.<< This form the 3rd Q PR, you may recall. And here it is plumbing bottom. I wonder if they have talked about partnering any of their unpartnered programs. failing that, I agree hibernation is the best thing. Am tempted to take a flyer at these levels. Cheers, Tuck